Delayed Neutrophil Recovery Following BCMA CAR-T Therapy in Duffy-null Myeloma Does Not Impact Severe Infections or Survival

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Oct 9

PMID 39383457

Authors

Zachary M Avigan

Saoirse Bodnar

Darren Pan

Jerrel Catlett

Joshua Richter

Larysa J Sanchez

Cesar Rodriguez

Adriana C Rossi

Shambavi Richard

Sundar Jagannath

Hearn Jay Cho

Samir Parekh

Santiago Thibaud

Affiliations

Soon will be listed here.

References

Hsieh M, Tisdale J, Rodgers G, Young N, Trimble E, Little R . Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?. J Clin Oncol. 2010; 28(10):1633-7. PMC: 2849762. DOI: 10.1200/JCO.2009.24.3881. View

Rejeski K, Hansen D, Bansal R, Sesques P, Ailawadhi S, Logue J . The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023; 16(1):88. PMC: 10391746. DOI: 10.1186/s13045-023-01465-x. View

Martin T, Usmani S, Berdeja J, Agha M, Cohen A, Hari P . Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2022; 41(6):1265-1274. PMC: 9937098. DOI: 10.1200/JCO.22.00842. View

Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P . Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023; 142(10):865-877. DOI: 10.1182/blood.2023020578. View

Rappoport N, Simon A, Amariglio N, Rechavi G . The Duffy antigen receptor for chemokines, ACKR1,- 'Jeanne DARC' of benign neutropenia. Br J Haematol. 2018; 184(4):497-507. DOI: 10.1111/bjh.15730. View

Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L . CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513. PMC: 8893508. DOI: 10.1182/blood.2020010543. View

Legge S, Christensen R, Petersen L, Pardinas A, Bracher-Smith M, Knapper S . The Duffy-null genotype and risk of infection. Hum Mol Genet. 2020; 29(20):3341-3349. PMC: 7906776. DOI: 10.1093/hmg/ddaa208. View

Sharma N, Reagan P, Liesveld J . Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem. Cancers (Basel). 2022; 14(6). PMC: 8946106. DOI: 10.3390/cancers14061501. View

Merz L, Story C, Osei M, Jolley K, Ren S, Park H . Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Adv. 2022; 7(3):317-320. PMC: 9881043. DOI: 10.1182/bloodadvances.2022007679. View

10.

Howes R, Patil A, Piel F, Nyangiri O, Kabaria C, Gething P . The global distribution of the Duffy blood group. Nat Commun. 2011; 2:266. PMC: 3074097. DOI: 10.1038/ncomms1265. View

11.

Duchene J, Novitzky-Basso I, Thiriot A, Casanova-Acebes M, Bianchini M, Etheridge S . Atypical chemokine receptor 1 on nucleated erythroid cells regulates hematopoiesis. Nat Immunol. 2017; 18(7):753-761. PMC: 5480598. DOI: 10.1038/ni.3763. View

12.

Juluri K, Wu Q, Voutsinas J, Hou J, Hirayama A, Mullane E . Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2021; 6(7):2055-2068. PMC: 9006285. DOI: 10.1182/bloodadvances.2020004142. View

13.

Rejeski K, Wang Y, Hansen D, Iacoboni G, Bachy E, Bansal R . Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024; 8(8):1857-1868. PMC: 11007437. DOI: 10.1182/bloodadvances.2023011767. View

14.

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T . Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787. PMC: 7422135. DOI: 10.1182/bloodadvances.2020002509. View

15.

Kanapuru B, Fernandes L, Baines A, Ershler R, Bhatnagar V, Pulte E . Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials. Blood. 2023; 142(3):235-243. DOI: 10.1182/blood.2022018657. View

16.

Tabbara N, Sharp J, Gaut D, Pham T, Tang K, Oliai C . Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias. Am J Hematol. 2022; 97(7):E249-E255. DOI: 10.1002/ajh.26551. View

17.

Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N . Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. J Immunother Cancer. 2023; 11(4). PMC: 10124318. DOI: 10.1136/jitc-2022-006406. View

18.

Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka A . Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023; 388(11):1002-1014. DOI: 10.1056/NEJMoa2213614. View

19.

Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bucklein V, Volkl S . Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023; 9(38):eadg3919. PMC: 10516499. DOI: 10.1126/sciadv.adg3919. View

20.

San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M . Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023; 389(4):335-347. DOI: 10.1056/NEJMoa2303379. View